Physician profile
Matthew Wayne Brooks
NPI 1831518208
$2,236.77
in general payments reported to CMS, 2019-2025
32 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $289 · 2021: $357 · 2022: $336 · 2023: $183 · 2024: $153 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $332.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $329.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $272.15 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $165.69 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $130.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $86.35 | 2019-2022 | |
| Baxter Healthcare | $79.53 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $76.65 | 2022-2025 | |
| Teleflex LLC | $64.18 | 2023-2024 | Urolift |
| Merck Sharp & Dohme LLC | $62.43 | 2019-2023 | Verquvo, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $55.03 | 2019 | |
| Boston Scientific Corporation | $50.60 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $45.54 | 2020-2021 | |
| Abbvie INC. | $38.08 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.67 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $28.04 | 2021 | |
| Medtronic, INC. | $25.32 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $24.10 | 2022 | |
| Esperion Therapeutics, INC. | $23.44 | 2021 | |
| Vital Connect, INC | $20.59 | 2023 | Vitalpatch Rtm |
| Astellas Pharma US INC | $19.57 | 2019 | |
| Si-Bone, INC. | $19.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.00 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $18.66 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2023 | Quviviq |
| Exact Sciences Corporation | $14.80 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $14.07 | 2025 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $13.98 | 2022 | |
| Allergan, INC. | $13.66 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.